Nicotine effects on affective response in depression-prone smokers.

Plain-language guide to PMID 17960366 (2008): double-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 17960366
Journal: Psychopharmacology
Year: 2008
Study type: Randomized Controlled Trial
Authors: Spring B et al. (8 authors)
DOI: 10.1007/s00213-007-0977-7

What This Study Did, in Plain Language

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

The researchers hypothesized that (1) nicotine would dispel negative affect and enhance positive affect and (2) effects would be stronger for smokers vulnerable to depression, particularly during a depressed state.

Who Took Part

The age groups tagged for this paper are teenagers and adults, both men and women.

Regular smokers (N = 165) were recruited from the community: 63 with no history of major depressive disorder (MDD), 61 with recurrent past but no current MDD, and 41 with both current and past MDD.

During four sessions, participants smoked either a nicotinized (NIC+) or denicotinized (NIC-) cigarette double blind after experiencing a negative mood induction or while undergoing a positive mood induction.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

Positive and negative affects were measured at baseline and at two time points after smoking.

What Was Measured

Topics PubMed links to this paper include Affect, Major Depressive Disorder, Nicotine, Nicotinic Agonists, Self Administration and Smoking.

What This Means in Plain Language

The paper is a randomized and double-blind study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.